Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$856M |
| 2 |
Meta Platforms (Facebook)
META
|
+$647M |
| 3 |
NVIDIA
NVDA
|
+$615M |
| 4 |
Berkshire Hathaway Class A
BRK.A
|
+$304M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$301M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$1.03B |
| 2 |
UnitedHealth
UNH
|
+$686M |
| 3 |
Tesla
TSLA
|
+$387M |
| 4 |
Abbott
ABT
|
+$380M |
| 5 |
Chevron
CVX
|
+$328M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.26% |
| 2 | Healthcare | 16.96% |
| 3 | Consumer Discretionary | 12.82% |
| 4 | Consumer Staples | 9.14% |
| 5 | Industrials | 9.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2751
Bolt Biotherapeutics
BOLT
$6.17M
| $619K | ﹤0.01% |
24,197
+1,360
| +6% | +$43.2K |
|
2752
Vanguard ESG US Stock ETF
ESGV
$13.7B
| $619K | ﹤0.01% |
+7,900
| New | +$582K |
|
2753
Wipro
WIT
$19.4B
| $617K | ﹤0.01% |
261,588
+178,188
| +214% | +$414K |
|
2754
iShares GSCI Commodity Dynamic Roll Strategy ETF
COMT
$1.22B
| $616K | ﹤0.01% |
23,700
-18,700
| -44% | -$492K |
|
2755
Cimpress
CMPR
$2.37B
| $613K | ﹤0.01% |
10,300
-9,000
| -47% | -$444K |
|
2756
ImmuCell
ICCC
$98.6M
| $612K | ﹤0.01% |
122,389
-438
| -0.4% | -$2.24K |
|
2757
Citizens
CIA
$198M
| $611K | ﹤0.01% |
253,494
-200
| -0.1% | -$459 |
|
2758
Moog Inc Class B
MOG.B
| $611K | ﹤0.01% |
5,800
| – | – |
|
|
LTCH
2759
DELISTED
Latch, Inc. Common Stock
LTCH
| $608K | ﹤0.01% |
437,700
+50,900
| +13% | +$47.6K |
|
2760
Hennessy Advisors
HNNA
$79M
| $606K | ﹤0.01% |
85,825
+4,550
| +6% | +$33.2K |
|
2761
Remitly
RELY
$5.39B
| $604K | ﹤0.01% |
32,100
-144,300
| -82% | -$2.62M |
|
|
ZH
2762
Zhihu
ZH
$274M
| $604K | ﹤0.01% |
89,150
-119,067
| -57% | -$782K |
|
2763
Mistras Group
MG
$584M
| $600K | ﹤0.01% |
77,700
+31,500
| +68% | +$234K |
|
2764
Wave Life Sciences
WVE
$1.02B
| $600K | ﹤0.01% |
164,820
+133,020
| +418% | +$537K |
|
2765
Design Therapeutics
DSGN
$901M
| $599K | ﹤0.01% |
95,108
-6,643
| -7% | -$40.7K |
|
2766
iShares MSCI Thailand ETF
THD
$354M
| $599K | ﹤0.01% |
9,100
-16,900
| -65% | -$1.18M |
|
2767
VSE Corp
VSEC
$6.48B
| $596K | ﹤0.01% |
10,900
+100
| +0.9% | +$4.83K |
|
|
YRD
2768
Yiren Digital
YRD
$105M
| $595K | ﹤0.01% |
261,465
-4,300
| -2% | -$9.96K |
|
|
GOEV
2769
DELISTED
Canoo Inc. Class A Common Stock
GOEV
| $595K | ﹤0.01% |
2,697
-6,562
| -71% | -$1.87M |
|
2770
iShares Global 100 ETF
IOO
$9.46B
| $593K | ﹤0.01% |
+7,800
| New | +$570K |
|
2771
MediWound
MDWD
$174M
| $593K | ﹤0.01% |
55,644
-1,200
| -2% | -$12.9K |
|
|
ACOR
2772
DELISTED
Acorda Therapeutics
ACOR
| $593K | ﹤0.01% |
45,561
+1,296
| +3% | +$15.4K |
|
2773
iShares S&P 500 Growth ETF
IVW
$77.9B
| $592K | ﹤0.01% |
8,400
-27,800
| -77% | -$1.84M |
|
|
TRST
2774
Trustco Bank Corp NY
TRST
$971M
| $592K | ﹤0.01% |
20,676
-13,300
| -39% | -$391K |
|
2775
Electromed
ELMD
$352M
| $591K | ﹤0.01% |
55,204
+1,700
| +3% | +$19.2K |
|
Similar funds
Jim Simons's Q2 2023 Portfolio in Review
As of Q2 2023, Jim Simons held 4,468 positions worth $69.4B, down 7.9% from $75.4B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Jim Simons withdrew a net $8.1B in Q2 2023, closing 599 positions and reducing 1,691 holdings. Its most notable exit was UnitedHealth, an estimated $686M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Jim Simons opened a new position in Berkshire Hathaway Class A worth $316M.
- Jim Simons's largest Q2 2023 buy was Berkshire Hathaway Class A: 611 shares worth $316M.
- Jim Simons added most to Apple in Q2 2023, an estimated $856M increase.
- Jim Simons's biggest Q2 2023 reduction was Amazon, cutting an estimated $1.03B.
- Jim Simons fully exited UnitedHealth in Q2 2023, selling an estimated $686M.
- Jim Simons's ten largest holdings make up 12% of its $69.4B portfolio in Q2 2023.
- Jim Simons opened 541 new positions and closed 599 in Q2 2023.
- Jim Simons's portfolio value fell 7.9% quarter-over-quarter to $69.4B.
Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.